Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

NCT03694834 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Endometrial Cancer
Uterine Cancer

Interventions

DRUG: Pembrolizumab
PROCEDURE: Hysterectomy

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]